Merrimack Pharmaceuticals... (MACK)
NASDAQ: MACK
· Real-Time Price · USD
15.14
0.01 (0.07%)
At close: May 17, 2024, 9:59 PM
Merrimack Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | -445K | -445K | -445K | -445K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 445K | 445K | 445K | 445K | 144K | 144K | 144K | 144K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | -890K | -890K | -890K | -890K | -144K | -144K | -144K | -144K | n/a | n/a | n/a |
Operating Income | -2.26M | -2.04M | -2.15M | -2.13M | -2.04M | -1.73M | -1.59M | -1.62M | -1.91M | -2.47M | -2.88M | -3.37M | -3.77M |
Interest Income | 925K | 868K | 724K | 534K | 364K | 188K | 71K | 9K | 20K | 20K | 20K | 21K | 5K |
Pretax Income | -1.33M | -1.17M | -1.43M | -1.59M | -1.68M | -1.54M | -1.52M | -1.61M | -1.89M | -2.45M | -3.07M | -3.56M | -3.96M |
Net Income | -24.54M | -1M | -1.26M | -1.3M | -1.37M | -1.4M | -1.39M | -1.59M | -1.89M | -2.46M | -3.09M | -3.57M | -3.97M |
Selling & General & Admin | 2.26M | 2.18M | 2.29M | 2.27M | 2.18M | 2.17M | 2.04M | 2.15M | 2.45M | 2.62M | 3.03M | 3.42M | 3.82M |
Research & Development | 139K | 278K | 139K | 139K | 139K | n/a | n/a | n/a | n/a | n/a | 11.1M | 11.1M | 11.1M |
Other Expenses | 139K | n/a | -139K | -139K | -139K | n/a | n/a | n/a | n/a | n/a | -209K | -209K | -209K |
Operating Expenses | 2.26M | 2.18M | 2.29M | 2.27M | 2.18M | 2.17M | 2.04M | 2.15M | 2.45M | 2.62M | 3.03M | 3.42M | 3.82M |
Interest Expense | 176K | 176K | n/a | 62K | 70K | 70K | 71K | 9K | 20K | 20K | 20K | 21K | 5K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.26M | 2.18M | 2.29M | 2.27M | 2.18M | 2.17M | 2.04M | 2.15M | 2.45M | 2.62M | 3.03M | 3.42M | 3.82M |
Income Tax Expense | 23.2M | -165.1K | -174.1K | -297.57K | -313K | -137K | -139K | -15K | 1K | 1K | -5.41M | -5.41M | -5.41M |
Shares Outstanding (Basic) | 14.45M | 14.34M | 14.32M | 14.29M | 14.25M | 13.77M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.4M |
Shares Outstanding (Diluted) | 14.45M | 14.34M | 14.32M | 14.29M | 14.25M | 13.77M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.4M |
EPS (Basic) | -1.7 | -0.07 | -0.09 | -0.09 | -0.1 | -0.1 | -0.1 | -0.12 | -0.14 | -0.18 | -0.23 | -0.27 | -0.3 |
EPS (Diluted) | -1.7 | -0.07 | -0.09 | -0.09 | -0.1 | -0.1 | -0.1 | -0.12 | -0.14 | -0.18 | -0.23 | -0.27 | -0.3 |
EBITDA | -2.26M | -2.31M | -2.43M | -2.4M | -2.32M | -2.62M | -2.48M | -2.69M | -2.99M | -2.76M | -2.62M | -2.91M | -3.32M |
EBIT | -52K | -499K | -447K | -827K | -1.3M | -982K | -1.45M | -1.6M | -1.87M | -2.43M | -3.05M | -3.53M | -3.95M |
Depreciation & Amortization | 169.59K | -151.69K | -335.5K | -268.83K | -304.85K | -916.85K | -777.85K | -992.93K | -1.02M | -233.19K | -440.19K | -251.19K | -286K |